-
公开(公告)号:US20200071669A1
公开(公告)日:2020-03-05
申请号:US16490568
申请日:2018-03-02
申请人: Yeda Research and Development Co. Ltd. , The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
发明人: Benjamin GEIGER , Nir FRIEDMAN , Shimrit LIEBER , Zelig ESHHAR , Tova WAKS , An at GLOBERSON LEVIN
IPC分类号: C12N5/0783 , A61K35/17
摘要: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.
-
2.
公开(公告)号:US20240139247A1
公开(公告)日:2024-05-02
申请号:US18408385
申请日:2024-01-09
申请人: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
IPC分类号: A61K35/17 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N5/10 , C12N15/63
CPC分类号: A61K35/17 , A61K39/001126 , A61K39/001129 , A61K39/3955 , A61K39/39558 , A61K39/4631 , A61P35/00 , C07K16/28 , C07K16/2896 , C07K16/3061 , C12N5/0636 , C12N5/10 , C12N15/63 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/569 , C07K2317/76 , C07K2319/03
摘要: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 scFv and the second CAR anti-CD138 scFv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.
-
公开(公告)号:US20230321235A1
公开(公告)日:2023-10-12
申请号:US18020441
申请日:2021-08-11
发明人: Yair REISNER , Anat GLOBERSON LEVIN , Esther BACHAR-LUSTIG , Assaf LASK , Bar NATHANSOHN-LEVI , Tova WAKS , Galit HORN , Zelig ESHHAR
IPC分类号: A61P35/00 , C12N5/0783 , A61K39/00
CPC分类号: A61K39/4611 , A61K39/4631 , A61P35/00 , C12N5/0636 , A61K2239/22 , C12N2510/00
摘要: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.
-
公开(公告)号:US20220204928A1
公开(公告)日:2022-06-30
申请号:US17604169
申请日:2020-04-16
发明人: Anat AHARON , Anat GLOBERSON LEVIN , Irit AVIVI , Galit HORN , Tova WAKS , Zelig ESHHAR
IPC分类号: C12N5/0783 , C07K16/32 , C07K14/705 , C07K14/725 , A61K45/06 , A61K39/395 , A61K38/17 , A61P35/00 , A61K35/17 , C07K16/28
摘要: The present invention provides extracellular vesicles (EVs) derived from T-cells expressing chimeric antigen receptors (CAR) specifically activated with an antigen to which the CAR bind specifically, pharmaceutical compositions comprising these vesicles as well as their use in treating cancer. In particular the present invention exemplifies EVs derived from activated T-cells expressing CAR that bind specifically to HER2 cancer antigen, pharmaceutical composition comprising these EVs and their use in treating a cancer overexpressing HER2, such as ovarian cancer and breast cancer.
-
公开(公告)号:US20130156794A1
公开(公告)日:2013-06-20
申请号:US13669194
申请日:2012-11-05
发明人: Zelig ESHHAR , Assaf MARCUS , Tova WAKS
IPC分类号: A61K35/14 , A61K31/4245 , A61K31/197 , A61K31/661 , A61K47/48 , A61N5/10 , A61K31/675 , A61K31/7076 , A61K31/185 , A61K31/196 , A61K39/395 , A61K31/135 , A61K48/00
CPC分类号: A61K35/17 , A61K31/135 , A61K31/137 , A61K31/185 , A61K31/196 , A61K31/197 , A61K31/4245 , A61K31/661 , A61K31/675 , A61K31/7076 , A61K39/39541 , A61K47/6891 , A61K48/00 , A61K2035/124 , A61N5/10 , B82Y5/00 , C07K16/32 , C07K2317/24 , C07K2317/622 , C07K2317/732 , C12N5/0636 , C12N5/0638 , C12N2501/2302 , C12N2501/50 , C12N2501/51 , C12N2501/515 , C12N2501/59 , C12N2501/599 , C12N2510/00
摘要: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.
摘要翻译: 通过向需要这种治疗的受试者施用有效量的具有MHC非限制性嵌合受体的部分淋巴结清除后短时间的有效量的同种异体T细胞来治疗疾病如癌症的方法。 所述方法还包括在将所述同种异体T细胞过继转移给受试者之前通过将T细胞捕获在淋巴结中来施用一种或多种在同种异体T细胞从所述受试者的淋巴结中释出出血的药剂。
-
公开(公告)号:US20170216356A1
公开(公告)日:2017-08-03
申请号:US15432534
申请日:2017-02-14
发明人: Zelig ESHHAR , Assaf MARCUS , Tova WAKS
IPC分类号: A61K35/17 , C12N5/0783 , A61K31/137 , C07K16/32 , A61K31/675
CPC分类号: A61K35/17 , A61K31/135 , A61K31/137 , A61K31/185 , A61K31/196 , A61K31/197 , A61K31/4245 , A61K31/661 , A61K31/675 , A61K31/7076 , A61K39/39541 , A61K47/6891 , A61K48/00 , A61K2035/124 , A61N5/10 , B82Y5/00 , C07K16/32 , C07K2317/24 , C07K2317/622 , C07K2317/732 , C12N5/0636 , C12N5/0638 , C12N2501/2302 , C12N2501/50 , C12N2501/51 , C12N2501/515 , C12N2501/59 , C12N2501/599 , C12N2510/00
摘要: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.
-
公开(公告)号:US20230058044A1
公开(公告)日:2023-02-23
申请号:US17779704
申请日:2020-11-25
发明人: Vered PADLER-KARAVANI , Yafit ATIYA-NASAGI , Ron AMON , Anat GLOBERSON LEVIN , Tova WAKS , Moran RAWET-SLOBODKIN , Lihi NINIO MANY , Zelig ESHHAR
IPC分类号: A61K35/17 , C07K14/725 , C07K14/705 , C07K14/735 , C12N5/0783
摘要: The present invention discloses chimeric antigen receptors that specifically recognize and bind to SLe A carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.
-
-
-
-
-
-